- Report
- January 2026
- 190 Pages
Global
From €3199EUR$3,545USD£2,780GBP
€3555EUR$3,939USD£3,088GBP
- Report
- March 2026
- 192 Pages
Global
From €5279EUR$5,850USD£4,587GBP
- Report
- January 2026
- 190 Pages
Global
From €3199EUR$3,545USD£2,780GBP
€3555EUR$3,939USD£3,088GBP
- Report
- December 2025
- 200 Pages
Global
From €7174EUR$7,950USD£6,233GBP
- Report
- March 2024
- 200 Pages
Global
From €3745EUR$4,150USD£3,254GBP
- Report
- April 2023
- 85 Pages
Global
From €4287EUR$4,750USD£3,724GBP
Carglumic acid is a drug used to treat endocrine and metabolic disorders. It is a synthetic form of N-carbamoyl-L-glutamate, an intermediate in the urea cycle. Carglumic acid is used to treat N-acetylglutamate synthase (NAGS) deficiency, an inherited disorder that can cause ammonia to accumulate in the blood. It is also used to treat hyperammonemia, a condition in which the body has too much ammonia in the blood. Carglumic acid works by helping the body break down ammonia and other nitrogen-containing compounds.
Carglumic acid is available in tablet and powder form. It is usually taken once or twice a day, depending on the condition being treated. Common side effects include nausea, vomiting, and diarrhea.
The carglumic acid market is a niche market, with few companies offering the drug. Companies in the market include Orphan Europe, Orphan Technologies, and Orphan Canada. Show Less Read more